Royalty Report: Diagnostic, Alzheimer’s disease, Drugs – Collection: 274655


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Diagnostic
  • Alzheimer’s disease
  • Drugs
  • Disease
  • Medical
  • Device
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 274655

License Grant
The German University granted an exclusive license to the University’s patent that underlies the Lympro Test.
License Property
The LymPro Test® is an immune-based neurodiagnostic blood test originally developed as a diagnostic blood test for detection of Alzheimer’s disease.
Field of Use
The field of use is to develop and commercialize the LymPro Test® for the detection of Alzheimer’s disease.

IPSCIO Record ID: 310824

License Grant
The Israel Licensee has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ®,

Pursuant to the agreement, the Licensor will receive royalty payments on the LymPro intellectual property in addition to being issued 49.9% of its ordinary shares in exchange for equity interest.

License Property
The LymPro intellectual property shall include the Lymphocyte Proliferation Test (LymPro Test®) which is a diagnostic blood test that determines the ability of peripheral blood lymphocytes to withstand an external mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons. LymPro is unique in the use of peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain.

Licensor is a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine to diagnose Alzheimer’s disease.

Field of Use
The field of use is to develop and commercialize the LymPro Test® for the detection of Alzheimer’s disease.

Licensee aims to develop and bring to market its revolutionary blood tests for disease detection that includes Alzheimers disease.

IPSCIO Record ID: 7312

License Grant
The Licensor hereby grants the Licensee an exclusive worldwide License to develop, manufacture, have manufactured, use, market, sell and import medical devices and methods under the Licensor Alzheimer’s disease Intellectual Property, including but not limited to the items of intellectual property detailed below, and to use all trademarks and copyrights related to the Licensor Intellectual Property in furtherance of such activities.
License Property
The Licensee may sell, sub-License or assign this Agreement to a third party at any time. In the event such sale occurs, the third party will be solely responsible for all of the payments scheduled to be made herein.

Alzheimer’s Disease Diagnostic IP
LymPro Test Intellectual Property
Issued Patents
· DE 19936035 Germany 05/13/2003
· DE 10349162 Germany 10/22/2003
· 223322 India 09/09/2008
· 2006/03178 South Africa 07/25/2007
· EP 1876449 (AI) Germany 07/07/2006
· PCT/EP2004/010889 PCT 09/24/2004
· PCT/EP2007/006028 PCT 07/06/2007

Field of Use
LymPro is a blood test that allows for the diagnosis of Alzheimer’s disease, even in its earliest stages, based upon certain immunology based markers in the blood by evaluating the quantities and concentrations of certain biomarkers in the blood with a scientific relationship to Alzheimer’s based on cell cycling.

IPSCIO Record ID: 177999

License Grant
The Licensor grants a sole, non-exclusive license to use Licensor Patents, Licensor Trademarks and Know-how to the Belgium Licensee, to sell and perform the AD7C/TM/ Test in the Territory. The AD7C/TM/ test is for measuring levels of Alzheimers marker Neural Thread Protein (NTP) in cerebrospinal fluid (CSF).
License Property
The Licensor has developed the AD7C/TM/ Test to aid in the diagnosis of Alzheimers Disease and wishes to make the test available for sale in Europe.

U. S. Patent Number 8,050,559  Neural Thread Protein Gene Expression and Detection of Alzheimers Disease U. S. Patent Number 7,289,207  Method of Detecting Neurological Disease or Dysfunction

Field of Use
The Belgium Licensee has testing facilities and capabilities for conducting the Nymox AD7C/TM/ Test in Europe; and  to conduct sales and related operations in Europe.

IPSCIO Record ID: 6572

License Grant
Pursuant to an agreement dated February 9, 2009 between the Company, and the Licensor, a California Corporation, the Licensee, is obligated to make payments, from earnings generated from Research derived from the biological specimens from Parkinson's disease patients and control patients provided by the Licensor.
License Property
IP relates to biomarkers for Parkinson's disease.
Field of Use
The Field of Use apply to the healthcare industry.  Licensee has an ongoing collaboration with the Parkinson’s Institute to test known Parkinson’s Disease (PD) patients’ blood to identify biomarkers for Parkinson’s Disease from the human plasma proteome microarray marketed as PlasmaScanâ„¢.  Licensee is also using the H25K Whole Human Genome Microarray to examine PD samples and has identified the world’s first functional mRNA biomarkers for Parkinson’s Disease. An expanded patient study will be used to further validate the PD biomarkers.  Licensee is also working with Stanford University to test known Alzheimer’s patients’ blood to identify biomarkers for Alzheimer’s Disease using PlasmaScan and other tools.

IPSCIO Record ID: 262864

License Grant
Under the collaboration agreement, the German Company grants the partner an exclusive license to certain therapeutic antibodies for specific targets and receives license fees, research and development funding, milestone payments and/or, if a product is approved for marketing, sales royalties in return.  Through the Partnered Discovery Program, the Company generates antibody candidates for partners in the pharmaceutical and biotechnology industries. A HuCAL antibody targeting amyloid beta that is in phase 3 clinical testing by our partner for the treatment of Alzheimer’s disease is Gantenerumab.
License Property
Gantenerumab is a HuCAL antibody directed against amyloid beta (Aß) that is being developed for the treatment of Alzheimer’s disease. Aß denotes a group of peptides that are crucially involved in Alzheimer’s disease as the main component of the amyloid plaques found in the brains of Alzheimer’s patients. In phase 1 clinical trials, gantenerumab has been shown to reduce brain amyloid in mild-to-moderate Alzheimer’s disease patients. Gantenerumab is being investigated in several clinical studies to see if there is a positive effect from intervening at an early stage in the disease’s progression.
Field of Use
Gantenerumab is an investigational immunotherapy being developed to treat Alzheimer’s disease by potentially reducing beta-amyloid plaques in the brain.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.